Arcutis' Zoryve Cream Shows Promise in Treating Atopic Dermatitis in Infants as Young as Three Months
New Phase II trial data for roflumilast cream indicates a favorable safety profile and significant improvement in disease severity for infants with mild to moderate eczema, addressing a critical gap in pediatric dermatology.